# GO	NS	enrichment	name	ratio_in_study	ratio_in_pop	p_uncorrected	depth	study_count	p_fdr_bh	study_items
Amyotrophic lateral sclerosis	XX	e	n.a	8/162	54/19378	1.5056114928226507e-08	n.a	8	2.615247163032944e-05	CAMK1G, DPP6, KIF5A, MOBP, SCFD1, SOD1, TBK1, UNC13A
Blood protein levels	XX	e	n.a	42/162	2091/19378	5.4229937269837664e-08	n.a	42	4.7098700518854e-05	ADIPOQ, AGT, ANG, ANXA2, APOA1, APOE, APOH, ARG1, CAT, CCR2, CD7, CFH, CRP, CST3, CTSD, CXCL10, ENO1, FASN, GPX1, GRN, GSN, GSTM1, GSTM3, GSTP1, HAVCR1, MMP9, NME2, PARK7, PENK, PLAT, PNP, PON1, PYGL, SELPLG, SNCA, SOD3, SPP1, TAF15, TNF, TREM2, VEGFA, VWF
Cholesterol_ total	XX	e	n.a	7/162	121/19378	7.123959012627821e-05	n.a	7	0.0412392644495108	APOA1, APOE, HAVCR1, LDLR, PPARA, PPARG, VIM
C-reactive protein	XX	e	n.a	4/162	29/19378	9.496664237077909e-05	n.a	4	0.0412392644495108	APOE, CRP, IL6, TREM2
LDL cholesterol	XX	e	n.a	8/162	181/19378	0.0001442909168339	n.a	8	0.0487825948621318	APOA1, APOE, APOH, ATXN2, HAVCR1, LDLR, PPARA, PPARG
Subcortical brain region volumes	XX	e	n.a	3/162	14/19378	0.0001951029828406	n.a	3	0.0487825948621318	BCL2L1, GRN, MAPT
Alzheimer's disease (late onset)	XX	e	n.a	5/162	64/19378	0.0001965907680108	n.a	5	0.0487825948621318	APOE, BSG, CLU, SQSTM1, TREM2
Lipid metabolism phenotypes	XX	e	n.a	4/162	37/19378	0.0002506925639986	n.a	4	0.0544316229582016	ALB, APOA1, APOE, LDLR
Inflammatory bowel disease	XX	e	n.a	16/162	709/19378	0.000304873670283	n.a	16	0.0588406183646368	AHR, ATXN2, CCL2, CCR2, CNTF, FOS, GPX1, IFNG, MMP9, NOTCH1, PARK7, PLA2G4A, PTGS2, SHC1, TNF, UBQLN4
Corticobasal degeneration	XX	e	n.a	2/162	5/19378	0.0006832156486083	n.a	2	0.0847675415451956	MAPT, MOBP
Dementia with Lewy bodies	XX	e	n.a	2/162	5/19378	0.0006832156486083	n.a	2	0.0847675415451956	APOE, SNCA
Glomerular filtration rate (cystatin C)	XX	e	n.a	2/162	5/19378	0.0006832156486083	n.a	2	0.0847675415451956	ATXN2, CST3
Essential tremor	XX	e	n.a	2/162	5/19378	0.0006832156486083	n.a	2	0.0847675415451956	PPARGC1A, SLC1A2
Free cholesterol levels in large LDL	XX	e	n.a	2/162	5/19378	0.0006832156486083	n.a	2	0.0847675415451956	ALB, APOE
Diastolic blood pressure (cigarette smoking interaction)	XX	e	n.a	4/162	57/19378	0.0013171569813812	n.a	4	0.1369369196553987	AGT, ATXN2, MTHFR, NOS3
Total cholesterol levels in LDL	XX	e	n.a	2/162	7/19378	0.0014190354368435	n.a	2	0.1369369196553987	ALB, APOE
Intracranial volume	XX	e	n.a	2/162	7/19378	0.0014190354368435	n.a	2	0.1369369196553987	GRN, MAPT
Serum total cholesterol levels	XX	e	n.a	2/162	7/19378	0.0014190354368435	n.a	2	0.1369369196553987	ALB, APOE
Advanced age-related macular degeneration	XX	e	n.a	4/162	61/19378	0.0016957403316389	n.a	4	0.1550263661082518	APOE, CFH, MMP9, VEGFA
Parental longevity (father's age at death)	XX	e	n.a	2/162	8/19378	0.0018816654725249	n.a	2	0.1612453927758523	APOE, ATXN2
C-reactive protein levels	XX	e	n.a	3/162	30/19378	0.0019728265180629	n.a	3	0.1612453927758523	APOE, ARG1, CRP
Systolic blood pressure (cigarette smoking interaction)	XX	e	n.a	4/162	66/19378	0.0022676059276334	n.a	4	0.1612453927758523	AGT, ATXN2, MTHFR, NOS3
Parental longevity (combined parental attained age_ Martingale residuals)	XX	e	n.a	3/162	32/19378	0.0023808840515215	n.a	3	0.1612453927758523	APOE, ATXN2, LDLR
Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)	XX	e	n.a	3/162	32/19378	0.0023808840515215	n.a	3	0.1612453927758523	JUND, PPARG, VEGFA
Waist-to-hip ratio adjusted for BMI in non-smokers	XX	e	n.a	3/162	32/19378	0.0023808840515215	n.a	3	0.1612453927758523	JUND, PPARG, VEGFA
Metabolite levels	XX	e	n.a	5/162	111/19378	0.0024135752516823	n.a	5	0.1612453927758523	APOA1, APOE, LDLR, PON1, SIX2
Panic disorder	XX	e	n.a	2/162	10/19378	0.0029910420653947	n.a	2	0.1675948408900204	CLU, TNFRSF21
Cholesterol efflux capacity (ABCA-1 dependent assay)	XX	e	n.a	2/162	10/19378	0.0029910420653947	n.a	2	0.1675948408900204	APOA1, APOE
Brain imaging	XX	e	n.a	2/162	10/19378	0.0029910420653947	n.a	2	0.1675948408900204	APOE, EPHA4
Age-related macular degeneration (geographic atrophy)	XX	e	n.a	2/162	10/19378	0.0029910420653947	n.a	2	0.1675948408900204	CFH, SOD2
Parental longevity (mother's attained age)	XX	e	n.a	2/162	10/19378	0.0029910420653947	n.a	2	0.1675948408900204	APOE, ATXN2
Coronary artery disease	XX	e	n.a	10/162	433/19378	0.0035566476462554	n.a	10	0.1913699589049062	AGT, APOA1, APOE, APOH, ATXN2, CKB, LDLR, MTHFR, NOS3, VEGFA
Parental longevity (combined parental age at death)	XX	e	n.a	2/162	11/19378	0.0036356987011294	n.a	2	0.1913699589049062	APOE, ATXN2
HDL cholesterol	XX	e	n.a	7/162	237/19378	0.0038493432413567	n.a	7	0.1966561532422543	APOA1, APOE, ARHGEF28, ATXN2, MAP3K5, PPARG, VEGFA
Lipoprotein phospholipase A2 activity in cardiovascular disease	XX	e	n.a	2/162	13/19378	0.0050998210824853	n.a	2	0.2530968348650578	APOE, LDLR
Total cholesterol levels	XX	e	n.a	6/162	190/19378	0.0053180951891829	n.a	6	0.2565980928780754	APOA1, APOE, ATXN2, HAVCR1, LDLR, VIM
Low density lipoprotein cholesterol levels	XX	e	n.a	3/162	44/19378	0.005909170899847	n.a	3	0.256957627741033	APOE, LDLR, NR1H4
Lipoprotein-associated phospholipase A2 activity and mass	XX	e	n.a	2/162	14/19378	0.0059172740988148	n.a	2	0.256957627741033	APOE, LDLR
Response to quetiapine in schizophrenia	XX	e	n.a	2/162	14/19378	0.0059172740988148	n.a	2	0.256957627741033	IGF1, VCP
Homocysteine levels	XX	e	n.a	2/162	14/19378	0.0059172740988148	n.a	2	0.256957627741033	MTHFR, NOX4
Waist-to-hip ratio adjusted for BMI in active individuals	XX	e	n.a	3/162	46/19378	0.0066911768958136	n.a	3	0.2742979159728481	ARHGEF28, PPARG, VEGFA
Psychosis (atypical)	XX	e	n.a	2/162	15/19378	0.00679033413174	n.a	2	0.2742979159728481	PYGL, TNF
Sarcoidosis	XX	e	n.a	2/162	15/19378	0.00679033413174	n.a	2	0.2742979159728481	ANXA11, ATXN2
Alzheimer's disease	XX	e	n.a	3/162	48/19378	0.0075318917753004	n.a	3	0.291439374514067	APOE, CLU, TREM2
Sexual dimorphism in anthropometric traits	XX	e	n.a	2/162	16/19378	0.0077180260377933	n.a	2	0.291439374514067	PPARG, VEGFA
Progressive supranuclear palsy	XX	e	n.a	2/162	16/19378	0.0077180260377933	n.a	2	0.291439374514067	MAPT, MOBP
Coronary artery disease (myocardial infarction_ PTCA_ CABG_ angina or CIHD)	XX	e	n.a	4/162	94/19378	0.0080154423966906	n.a	4	0.2962302860223746	APOA1, APOE, LDLR, NOS3
Pulse pressure	XX	e	n.a	11/162	567/19378	0.0082432112059728	n.a	11	0.2983012055161427	APOE, CNTF, CYP2C9, GLT8D1, IL6, MTHFR, NOX4, SOD2, TP53, TRPM7, WNT7A
Triglyceride levels	XX	e	n.a	4/162	103/19378	0.0109715886304963	n.a	4	0.3795479011962221	APOA1, APOE, TLE3, VEGFA
Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	XX	e	n.a	3/162	56/19378	0.0115002014673688	n.a	3	0.3795479011962221	ARHGEF28, PPARG, VEGFA
Gut microbiota (functional units)	XX	e	n.a	3/162	56/19378	0.0115002014673688	n.a	3	0.3795479011962221	APOE, CCL2, PPARG
Hippocampal volume	XX	e	n.a	3/162	56/19378	0.0115002014673688	n.a	3	0.3795479011962221	APOE, CXCL10, HMGB1
Blood osmolality (transformed sodium)	XX	e	n.a	2/162	20/19378	0.0119560351842142	n.a	2	0.3795479011962221	ATXN2, HMGB1
Abdominal aortic aneurysm	XX	e	n.a	2/162	20/19378	0.0119560351842142	n.a	2	0.3795479011962221	LDLR, MMP9
Platelet count	XX	e	n.a	8/162	366/19378	0.012017924332638	n.a	8	0.3795479011962221	APOE, APOH, ATXN2, BCL2L1, EWSR1, MTPN, PPARG, VWF
Systolic blood pressure	XX	e	n.a	12/162	657/19378	0.0129428065720056	n.a	12	0.3936006992108449	AGT, APOA1, APOH, CNTF, CYP2C9, ERBB4, GLT8D1, IGF1, MTHFR, NOS3, NOX4, TRPM7
Alzheimer's disease in APOE e4+ carriers	XX	e	n.a	2/162	21/19378	0.0131426831054858	n.a	2	0.3936006992108449	CLU, SORD
Fasting blood insulin (BMI interaction)	XX	e	n.a	2/162	21/19378	0.0131426831054858	n.a	2	0.3936006992108449	IGF1, PPARG
Mean arterial pressure	XX	e	n.a	4/162	110/19378	0.0137010908602823	n.a	4	0.4033694038018724	AGT, ATXN2, MTHFR, NOS3
Waist-to-hip ratio adjusted for body mass index	XX	e	n.a	4/162	111/19378	0.0141230540605672	n.a	4	0.4088624150534216	ARHGEF28, JUND, PPARG, VEGFA
Ulcerative colitis	XX	e	n.a	9/162	456/19378	0.0146765436927181	n.a	9	0.4179205966270715	AHR, CCR2, CNTF, GPX1, IFNG, NOTCH1, PARK7, PRKCD, TNF
Lipid traits	XX	e	n.a	2/162	23/19378	0.0156621870497183	n.a	2	0.4318288715136622	APOA1, APOE
Parental longevity (father's attained age)	XX	e	n.a	2/162	23/19378	0.0156621870497183	n.a	2	0.4318288715136622	APOE, ATXN2
LDL cholesterol levels	XX	e	n.a	3/162	64/19378	0.0164701224054737	n.a	3	0.4340780869844914	APOA1, APOE, LDLR
Diabetic kidney disease	XX	e	n.a	2/162	24/19378	0.0169932699567906	n.a	2	0.4340780869844914	ANXA11, MAT1A
Waist-to-hip ratio adjusted for BMI x sex interaction	XX	e	n.a	2/162	24/19378	0.0169932699567906	n.a	2	0.4340780869844914	RXRA, VEGFA
Relative hand skill in reading disability	XX	e	n.a	2/162	24/19378	0.0169932699567906	n.a	2	0.4340780869844914	ACTB, SLC1A2
Cerebrospinal fluid p-tau levels	XX	e	n.a	2/162	24/19378	0.0169932699567906	n.a	2	0.4340780869844914	APOE, OPTN
Rheumatoid arthritis	XX	e	n.a	5/162	182/19378	0.018543144300656	n.a	5	0.4549987747415634	ATG5, CSF3, IRAK1, KIF5A, TLE3
Ischemic stroke	XX	e	n.a	3/162	67/19378	0.0185981076607087	n.a	3	0.4549987747415634	FGA, LDLR, PARK7
Age-related macular degeneration	XX	e	n.a	3/162	67/19378	0.0185981076607087	n.a	3	0.4549987747415634	APOE, CFH, VEGFA
Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)	XX	e	n.a	3/162	68/19378	0.0193397362863172	n.a	3	0.4577975181095298	JUND, PPARG, VEGFA
Triglycerides	XX	e	n.a	5/162	184/19378	0.0193411014774563	n.a	5	0.4577975181095298	APOA1, APOE, APOH, HAVCR1, VEGFA
Crohn's disease	XX	e	n.a	11/162	613/19378	0.0195031757858982	n.a	11	0.4577975181095298	ATXN2, CCL2, FOS, GPX1, LAT, NOTCH1, PARK7, PLA2G4A, PTGS2, TNF, UBQLN4
Cerebrospinal fluid p-tau levels in mild cognitive impairment	XX	e	n.a	2/162	26/19378	0.0197937490663021	n.a	2	0.4584232283755579	APOE, OPTN
Knee osteoarthritis	XX	e	n.a	2/162	27/19378	0.0212614390089108	n.a	2	0.4796249293308856	PLA2G4A, PTGS2
Metabolite levels (lipoprotein measures)	XX	e	n.a	2/162	27/19378	0.0212614390089108	n.a	2	0.4796249293308856	APOE, LDLR
High density lipoprotein cholesterol levels	XX	e	n.a	3/162	71/19378	0.0216617609216927	n.a	3	0.4823907528330808	APOE, PPARG, VEGFA
Celiac disease	XX	e	n.a	4/162	130/19378	0.0237418141678114	n.a	4	0.5220193823985879	ATXN2, CCR2, IRAK1, PARK7
Hypothyroidism	XX	e	n.a	3/162	75/19378	0.0249846698368683	n.a	3	0.5424796438330036	ATXN2, CCL2, VEGFA
Adiponectin levels	XX	e	n.a	2/162	30/19378	0.0259243004030721	n.a	2	0.5491525585382482	ADIPOQ, VEGFA
Very long-chain saturated fatty acid levels (fatty acid 20:0)	XX	e	n.a	2/162	30/19378	0.0259243004030721	n.a	2	0.5491525585382482	APOE, PPARA
Coronary heart disease	XX	e	n.a	3/162	77/19378	0.0267432902421293	n.a	3	0.5596758451876958	APOA1, LDLR, VEGFA
Glomerular filtration rate (creatinine)	XX	e	n.a	3/162	81/19378	0.030454247506649	n.a	3	0.6223415049299921	DHFR, VEGFA, WNT7A
Chronic kidney disease	XX	e	n.a	3/162	81/19378	0.030454247506649	n.a	3	0.6223415049299921	ATXN2, CST3, VEGFA
Systemic lupus erythematosus	XX	e	n.a	7/162	365/19378	0.034046883068012	n.a	7	0.6673825876330797	ATG5, ATXN2, CFH, IFNG, IRAK1, PLAT, PPARG
Activated partial thromboplastin time	XX	e	n.a	2/162	36/19378	0.0363468529773538	n.a	2	0.6673825876330797	ADIPOQ, APOH
Chronic obstructive pulmonary disease-related biomarkers	XX	e	n.a	2/162	36/19378	0.0363468529773538	n.a	2	0.6673825876330797	ANXA11, WNT7A
Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)	XX	e	n.a	2/162	37/19378	0.0382170913942107	n.a	2	0.6673825876330797	ATXN2, IL6
Nose size	XX	e	n.a	2/162	39/19378	0.0420649917415712	n.a	2	0.6717106490531507	EPHA4, GSTA4
HDL cholesterol levels	XX	e	n.a	3/162	93/19378	0.0431178305554482	n.a	3	0.6717106490531507	APOA1, APOE, VEGFA
Fibrinogen	XX	e	n.a	2/162	40/19378	0.0440412126018141	n.a	2	0.6717106490531507	FGA, IL6
Hypertriglyceridemia	XX	e	n.a	2/162	41/19378	0.0460513355505167	n.a	2	0.6717106490531507	APOA1, HAVCR1
Diastolic blood pressure x alcohol consumption interaction (2df test)	XX	e	n.a	3/162	96/19378	0.0466356523244713	n.a	3	0.6717106490531507	AGT, ATXN2, NOS3
Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)	XX	e	n.a	2/162	42/19378	0.0480946634161755	n.a	2	0.6717106490531507	ATXN2, MTHFR
Lipoprotein (a) levels	XX	e	n.a	2/162	42/19378	0.0480946634161755	n.a	2	0.6717106490531507	APOE, SOD2
Blood pressure	XX	e	n.a	3/162	98/19378	0.0490573363951113	n.a	3	0.6717106490531507	ATXN2, MTHFR, RXRA
Cognitive decline (age-related)	XX	e	n.a	2/162	43/19378	0.0501705081918671	n.a	2	0.6717106490531507	APOE, SCFD1
Atrial fibrillation	XX	e	n.a	5/162	240/19378	0.0513492688680703	n.a	5	0.6717106490531507	ERBB4, KIF3C, MAPT, MTHFR, TLE3
Alzheimer's disease in APOE e4- carriers	XX	e	n.a	2/162	44/19378	0.0522781909206699	n.a	2	0.6717106490531507	CLU, MAPT
Metabolic traits	XX	e	n.a	2/162	46/19378	0.0565863990858705	n.a	2	0.6717106490531507	AHR, CRP
Primary biliary cirrhosis	XX	e	n.a	2/162	47/19378	0.0587856109882312	n.a	2	0.6717106490531507	ATXN2, MAPT
Creatine kinase levels	XX	e	n.a	2/162	48/19378	0.0610140335596876	n.a	2	0.6717106490531507	APOH, CSF3
ALT levels after remission induction therapy in actute lymphoblastic leukemia (ALL)	XX	e	n.a	2/162	48/19378	0.0610140335596876	n.a	2	0.6717106490531507	AHR, DCTN1
Chronic inflammatory diseases (pleiotropy)	XX	e	n.a	4/162	177/19378	0.0614794138737734	n.a	4	0.6717106490531507	ERN1, FOS, NOTCH1, PARK7
Reticulocyte fraction of red cells	XX	e	n.a	4/162	180/19378	0.0645729340424326	n.a	4	0.6717106490531507	APOE, ATXN2, TAF15, VEGFA
Glomerular filtration rate	XX	e	n.a	3/162	111/19378	0.0662442817701905	n.a	3	0.680865783637994	ARG1, ERBB4, VEGFA
Diastolic blood pressure	XX	e	n.a	10/162	646/19378	0.0718122349343126	n.a	10	0.7023939220776986	AGT, APOA1, ATXN2, CNTF, CYP2C9, MTHFR, NOS3, RIPK3, TP53, VEGFA
Systolic blood pressure x alcohol consumption interaction (2df test)	XX	e	n.a	3/162	115/19378	0.0720181259607052	n.a	3	0.7023939220776986	AGT, ATXN2, NOS3
Serum total protein level	XX	e	n.a	2/162	54/19378	0.0749630100477723	n.a	2	0.7156739114131156	ATXN2, TLE3
QT interval	XX	e	n.a	3/162	117/19378	0.0749871340686166	n.a	3	0.7156739114131156	CREBBP, DPP6, TRPM7
Lung adenocarcinoma	XX	e	n.a	3/162	123/19378	0.0842126498911808	n.a	3	0.7368276142299309	CLU, TBK1, TLE3
Waist-hip ratio	XX	e	n.a	2/162	58/19378	0.0847692202149648	n.a	2	0.7368276142299309	PPARG, VEGFA
Eosinophil counts	XX	e	n.a	4/162	199/19378	0.086001124509375	n.a	4	0.7368276142299309	ATXN2, BAX, PPARG, SHC1
Thiazide-induced adverse metabolic effects in hypertensive patients	XX	e	n.a	2/162	60/19378	0.0898106125914272	n.a	2	0.7464164309632011	IGF1, PPARGC1A
Resting heart rate	XX	e	n.a	3/162	127/19378	0.0906198659408408	n.a	3	0.7495557482820976	APOE, CANX, PPARGC1A
Waist circumference adjusted for body mass index	XX	e	n.a	3/162	128/19378	0.0922527741444463	n.a	3	0.7594458231701581	JUND, TLE3, VEGFA
Reaction time	XX	e	n.a	2/162	65/19378	0.1027826706988908	n.a	2	0.8165689404540517	ATXN2, MAPT
Glycated hemoglobin levels	XX	e	n.a	2/162	66/19378	0.1054361090313419	n.a	2	0.8269244078317824	ATXN2, SIX2
Systemic sclerosis	XX	e	n.a	2/162	68/19378	0.1107979963667115	n.a	2	0.8269244078317824	ATG5, MMP9
Myeloid white cell count	XX	e	n.a	3/162	140/19378	0.1127678487038802	n.a	3	0.8370844153788036	CANX, CSF3, VEGFA
Waist circumference adjusted for BMI in non-smokers	XX	e	n.a	2/162	69/19378	0.1135054724687123	n.a	2	0.8389744922474609	JUND, VEGFA
Tuberculosis	XX	e	n.a	2/162	72/19378	0.1217283344703402	n.a	2	0.8639051804159212	HTT, MTHFR
Stroke	XX	e	n.a	2/162	73/19378	0.1245012226367216	n.a	2	0.8639051804159212	FGA, LDLR
Rheumatoid arthritis (ACPA-positive)	XX	e	n.a	2/162	74/19378	0.1272893222315332	n.a	2	0.8639051804159212	IRAK1, TLE3
Migraine	XX	e	n.a	2/162	74/19378	0.1272893222315332	n.a	2	0.8639051804159212	FGF6, INA
Longevity	XX	e	n.a	2/162	74/19378	0.1272893222315332	n.a	2	0.8639051804159212	APOE, IL6
Urate levels	XX	e	n.a	2/162	74/19378	0.1272893222315332	n.a	2	0.8639051804159212	ATXN2, VEGFA
Neutrophil percentage of granulocytes	XX	e	n.a	3/162	148/19378	0.1273228130031524	n.a	3	0.8639051804159212	ATXN2, BAX, PPARG
Plateletcrit	XX	e	n.a	4/162	231/19378	0.1287612922772031	n.a	4	0.8702660104494235	APOH, ATXN2, BCL2L1, ENO1
Monobrow	XX	e	n.a	2/162	76/19378	0.1329093866423215	n.a	2	0.8703998702642347	ATG5, HTT
Waist-to-hip ratio adjusted for BMI (age <50)	XX	e	n.a	3/162	153/19378	0.136744144822479	n.a	3	0.8703998702642347	HNRNPA2B1, PPARG, VEGFA
Hematocrit	XX	e	n.a	3/162	153/19378	0.136744144822479	n.a	3	0.8703998702642347	ATXN2, PPARG, VEGFA
Extremely high intelligence	XX	e	n.a	2/162	78/19378	0.1385850519044219	n.a	2	0.8703998702642347	CKB, GPX1
Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	XX	e	n.a	2/162	79/19378	0.1414426755402568	n.a	2	0.8743271438200215	JUND, VEGFA
Waist circumference adjusted for BMI (adjusted for smoking behaviour)	XX	e	n.a	2/162	81/19378	0.1471954388142492	n.a	2	0.8927088933523065	JUND, VEGFA
Type 2 diabetes	XX	e	n.a	6/162	397/19378	0.1508953905536912	n.a	6	0.9100878242769505	ACSL1, ANXA2, APOE, ARG1, PPARG, VEGFA
Waist-to-hip ratio adjusted for BMI (age >50)	XX	e	n.a	4/162	250/19378	0.1576200179224992	n.a	4	0.9213366361229935	HMOX1, HNRNPA2B1, PPARG, VEGFA
Waist circumference adjusted for BMI in active individuals	XX	e	n.a	2/162	85/19378	0.1588398291472826	n.a	2	0.9213366361229935	TLE3, VEGFA
Male-pattern baldness	XX	e	n.a	4/162	251/19378	0.1592017802493633	n.a	4	0.9213366361229935	MAPT, PDGFA, TARDBP, TLE3
Venous thromboembolism adjusted for sickle cell variant rs77121243-T	XX	e	n.a	2/162	86/19378	0.1617775901079522	n.a	2	0.9213366361229935	DPP6, MTPN
Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	XX	e	n.a	2/162	87/19378	0.1647252617196111	n.a	2	0.9350581032907338	TLE3, VEGFA
Platelet distribution width	XX	e	n.a	3/162	170/19378	0.1704177689458176	n.a	3	0.9457369477919652	ATXN2, MTPN, TUBA4A
Reticulocyte count	XX	e	n.a	3/162	171/19378	0.1724692371602427	n.a	3	0.947698038542641	APOE, TAF15, VEGFA
High light scatter reticulocyte percentage of red cells	XX	e	n.a	3/162	172/19378	0.1745277995917846	n.a	3	0.947698038542641	APOE, ATXN2, VEGFA
Allergic disease (asthma_ hay fever or eczema)	XX	e	n.a	3/162	172/19378	0.1745277995917846	n.a	3	0.947698038542641	ATG5, ATXN2, IL1B
Cognitive function	XX	e	n.a	2/162	92/19378	0.1795995958128868	n.a	2	0.9639610323691548	GFAP, TLE3
Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	XX	e	n.a	2/162	94/19378	0.1856062416301491	n.a	2	0.97401221060897	ATXN2, MTHFR
Alopecia areata	XX	e	n.a	2/162	94/19378	0.1856062416301491	n.a	2	0.97401221060897	ATXN2, IFNG
Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	XX	e	n.a	2/162	96/19378	0.1916413563738369	n.a	2	0.984855136157854	ATXN2, MTHFR
Creatinine levels	XX	e	n.a	2/162	97/19378	0.194668776627931	n.a	2	0.9936260711209144	ARG1, VEGFA
Amyotrophic lateral sclerosis (sporadic)	XX	e	n.a	3/162	182/19378	0.1954776930779378	n.a	3	0.9936260711209144	ERBB4, MOBP, UNC13A
Bipolar disorder	XX	e	n.a	3/162	194/19378	0.2213747867271169	n.a	3	1.0	GLT8D1, PC, PRKCD
Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	XX	e	n.a	2/162	109/19378	0.2313917364092787	n.a	2	1.0	ATXN2, MTHFR
Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	XX	e	n.a	2/162	112/19378	0.2406519492749045	n.a	2	1.0	ATXN2, MTHFR
Allergic rhinitis	XX	e	n.a	2/162	114/19378	0.2468355701965177	n.a	2	1.0	APOA1, ATXN2
Itch intensity from mosquito bite adjusted by bite size	XX	e	n.a	2/162	117/19378	0.2561213252461564	n.a	2	1.0	HTT, IFNG
Major depressive disorder	XX	e	n.a	3/162	212/19378	0.2613693025015081	n.a	3	1.0	FASN, MAP1LC3B, SOD3
Vitiligo	XX	e	n.a	2/162	121/19378	0.2685118102147776	n.a	2	1.0	ATXN2, SLC1A2
Colorectal cancer	XX	e	n.a	2/162	124/19378	0.2778040131463785	n.a	2	1.0	ABCC2, FGF6
Immature fraction of reticulocytes	XX	e	n.a	2/162	125/19378	0.2809001572379986	n.a	2	1.0	APOE, ATXN2
Cognitive decline rate in late mild cognitive impairment	XX	e	n.a	2/162	126/19378	0.2839953325390371	n.a	2	1.0	GABRA1, PPARGC1A
Hemoglobin concentration	XX	e	n.a	2/162	128/19378	0.2901819839242807	n.a	2	1.0	PPARG, VEGFA
Pancreatic cancer	XX	e	n.a	2/162	130/19378	0.29636241468018	n.a	2	1.0	DPP6, EWSR1
Rosacea symptom severity	XX	e	n.a	2/162	141/19378	0.33017907291983	n.a	2	1.0	AHR, PPARGC1A
Neuroticism	XX	e	n.a	2/162	142/19378	0.3332338591009604	n.a	2	1.0	MAP1LC3B, MAPT
Alcoholic chronic pancreatitis	XX	e	n.a	2/162	145/19378	0.3423740869646403	n.a	2	1.0	MTPN, TLE3
Eosinophil percentage of granulocytes	XX	e	n.a	2/162	152/19378	0.3635424599334877	n.a	2	1.0	ATXN2, PPARG
Lung cancer in ever smokers	XX	e	n.a	2/162	153/19378	0.3665464111311042	n.a	2	1.0	AHR, CLU
Blood metabolite levels	XX	e	n.a	2/162	158/19378	0.3814827828203303	n.a	2	1.0	AHR, CYP2C9
Granulocyte percentage of myeloid white cells	XX	e	n.a	2/162	159/19378	0.3844525765984878	n.a	2	1.0	CCR2, CSF3
Eosinophil percentage of white cells	XX	e	n.a	2/162	160/19378	0.3874162862465304	n.a	2	1.0	ATXN2, PPARG
Blond vs. brown/black hair color	XX	e	n.a	2/162	160/19378	0.3874162862465304	n.a	2	1.0	EPHA4, IL6
Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	XX	e	n.a	5/162	419/19378	0.4052592307231789	n.a	5	1.0	HMOX1, HNRNPA1, HNRNPA2B1, PPARG, VEGFA
White blood cell count	XX	e	n.a	3/162	227/19378	0.44242137603551	n.a	3	1.0	CANX, CSF3, VEGFA
Heel bone mineral density	XX	e	n.a	9/162	898/19378	0.5700824680185806	n.a	9	1.0	CD68, CREBBP, EPHA4, MMP2, MMP9, PPARG, RIPK3, TLE3, VEGFA
Monocyte percentage of white cells	XX	e	n.a	2/162	171/19378	0.6560578697052311	n.a	2	1.0	BCL2L1, CCR2
High light scatter reticulocyte count	XX	e	n.a	2/162	172/19378	0.6569464190936796	n.a	2	1.0	APOE, ATXN2
Sum eosinophil basophil counts	XX	e	n.a	2/162	173/19378	0.6578443895404693	n.a	2	1.0	ATXN2, BAX
Parkinson's disease	XX	e	n.a	2/162	184/19378	0.6682832961866331	n.a	2	1.0	MAPT, SNCA
Macular thickness	XX	e	n.a	2/162	191/19378	0.6753830707718297	n.a	2	1.0	GSX2, TLE3
Spherical equivalent or myopia (age of diagnosis)	XX	e	n.a	2/162	191/19378	0.6753830707718297	n.a	2	1.0	CLU, DPP6
Breast cancer	XX	e	n.a	2/162	219/19378	0.7060718956395736	n.a	2	1.0	ERBB4, EWSR1
Monocyte count	XX	e	n.a	2/162	224/19378	0.7117838414365463	n.a	2	1.0	ATXN2, CCR2
Lung cancer	XX	e	n.a	2/162	225/19378	0.712930594197963	n.a	2	1.0	CRP, SIX2
Red cell distribution width	XX	e	n.a	2/162	230/19378	0.7186805429800317	n.a	2	1.0	APOE, NOTCH1
Mean corpuscular volume	XX	p	n.a	2/162	365/19378	0.7730232218175949	n.a	2	1.0	ATXN2, HMGB1
Intelligence (MTAG)	XX	p	n.a	2/162	366/19378	0.7730612062941127	n.a	2	1.0	ERBB4, GPX1
Body mass index	XX	p	n.a	10/162	1246/19378	1.0	n.a	10	1.0	APOE, ATXN2, CALB2, CKB, ERBB4, GLE1, MATR3, PPARG, VEGFA, WNT7A
Prostate cancer	XX	p	n.a	3/162	399/19378	1.0	n.a	3	1.0	ALB, PRPH, SHC1
Intraocular pressure	XX	p	n.a	3/162	401/19378	1.0	n.a	3	1.0	ATXN2, IGF1, RXRA
Height	XX	p	n.a	4/162	527/19378	1.0	n.a	4	1.0	IGF1, NME2, PENK, TLE3
Autism spectrum disorder or schizophrenia	XX	p	n.a	6/162	752/19378	1.0	n.a	6	1.0	CKB, CLU, GLT8D1, INA, NEK1, TNF
Obesity-related traits	XX	p	n.a	6/162	804/19378	1.0	n.a	6	1.0	CCR2, CREBBP, CYP2E1, HMOX1, NOX4, UNC13A
Night sleep phenotypes	XX	p	n.a	4/162	555/19378	1.0	n.a	4	1.0	ACSL1, ANXA2, NEK1, SCFD1
Waist-to-hip ratio adjusted for BMI	XX	p	n.a	3/162	367/19378	1.0	n.a	3	1.0	HNRNPA2B1, PPARG, VEGFA
Mean corpuscular hemoglobin	XX	p	n.a	2/162	336/19378	1.0	n.a	2	1.0	HMGB1, TP53
Schizophrenia	XX	p	n.a	7/162	882/19378	1.0	n.a	7	1.0	CKB, CLU, GLT8D1, INA, NEK1, PPARGC1A, TLE3